Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Results and Revenue Performance
BIIB logo

Biogen Net Income Surges 33% Amid $5.6 Billion Apellis Merger Agreement

BIIB10-QFiling Date: 4/29/2026
Biogen Inc.
Description

What this story covers

Biogen's Q1 2026 results show a 33% net income surge and a $5.6 billion Apellis merger. Despite TECFIDERA's 47% sales drop, growth in Alzheimer's and rare disease therapies signals a successful portfolio transition and strong financial footing.

Story snapshot

CompanyBiogen Inc.
TickerBIIB
VariantStandard detailed
Duration10:02
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000875045-26-000045
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in